Company profile
Draupnir Bio
Bringing innovative therapies to patients
- Industry
- Biotechnology Research
- Employees
- 16
- Headquarters
- Copenhagen
- Founded
- 2017
- Office locations
- 2
Draupnir Bio company summary
Draupnir Bio is a company in the Biotechnology Research industry, headquartered in Copenhagen, founded in 2017. On LinkedIn the company has around 16 employees. The company lists 2 office locations. Its listed specialties include biotechnology, biotech, targeted protein degradation, membrane-bound proteins, extracellular targets.
What technology does Draupnir Bio use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Draupnir Bio
Draupnir Bio is a Danish biotechnology company driven by a deep commitment to scientific excellence and the desire to bring innovative therapies to patients in need. By harnessing the natural machinery of the lysosome, we are developing oral, small molecule degraders of extracellular pathogenic proteins – the next frontier of targeted protein degradation (TPD), a rapidly emerging field that exploits a cell’s own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies. First-generation TPD approaches are exclusively limited to intracellular targets, leaving extracellular and membrane-bound proteins – 40% of the human proteome – untouched. At Draupnir, we are extending the potential of TPD to both extracellular and membrane-bound proteins in a pioneering approach using our novel and differentiated, proprietary technology platform which targets lysosome receptors and has the potential to revolutionise the field of TPD. Led by a highly experienced team of pharma and biotech industry leaders, Draupnir is a spin-out from Aarhus University, Denmark and the Max-Planck Society, Germany and is backed by a syndicate of leading European investors.
Specialties
Where is Draupnir Bio located?
Draupnir Bio lists 2 office locations.
Compare companies similar to Draupnir Bio
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Draupnir Bio draupnir.bio | Biotechnology Research | 16 | 2017 | Copenhagen |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Draupnir Bio
What does Draupnir Bio do?
Draupnir Bio is a Danish biotechnology company driven by a deep commitment to scientific excellence and the desire to bring innovative therapies to patients in need. By harnessing the natural machinery of the lysosome, we are developing oral, small molecule degraders of extracellular pathogenic proteins – the next frontier of targeted protein degradation (TPD), a rapidly emerging field that exploits a cell’s own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies. First-generation TPD approaches are exclusively limited to intracellular targets, leaving extracellular and membrane-bound proteins – 40% of the human proteome – untouched. At Draupnir, we are extending the potential of TPD to both extracellular and membrane-bound proteins in a pioneering approach using our novel and differentiated, proprietary technology platform which targets lysosome receptors and has the potential to revolutionise the field of TPD. Led by a highly experienced team of pharma and biotech industry leaders, Draupnir is a spin-out from Aarhus University, Denmark and the Max-Planck Society, Germany and is backed by a syndicate of leading European investors.
How many employees does Draupnir Bio have?
Draupnir Bio has around 16 employees on LinkedIn.
Where is Draupnir Bio headquartered?
Draupnir Bio is headquartered in Copenhagen.
Where does Draupnir Bio have offices?
Draupnir Bio lists 2 office locations, including Copenhagen, DK, DK; Aarhus, DK, DK.
When was Draupnir Bio founded?
Draupnir Bio was founded in 2017.
Build a lead list from companies like Draupnir Bio
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.